Since 1971, the landscape of drug research in the United States has been drastically altered, with severe restrictions placed on the study of substances deemed “most dangerous.” The Controlled Substances Act (CSA), ostensibly implemented for public protection, has instead created a system that inadvertently benefits pharmaceutical companies by maintaining their monopoly on drug manufacturing and distribution.
The Trump administration is preparing to move cannabis from Schedule I to Schedule III of…
Based on the ruling, products that are legal federally as well as at the state…
The drug’s history of healing and experimentation stretches from ancient China to American counterculture —…
The new partnership will spotlight the stories of people still behind bars for cannabis, support…
Colombia is moving forward with a controversial plan to euthanize dozens of invasive hippos descended…
Imported hashish sustained mountain economies for centuries—until modern legalization and market economics erased it almost…